ArticleEJHaem2023

A phase III, randomised, double-blind, multi-national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria.

Jun Ho Jang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.